Mittal D - Search Results

1

Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice.

Overman J, Fontaine F, Moustaqil M, Mittal D, Sierecki E, Sacilotto N, Zuegg J, Robertson AAB, Holmes K, Salim AA, Mamidyala S, Butler MS, Robinson AS, Lesieur E, Johnston W, Alexandrov K, Black BL, Hogan BM, De Val S, Capon RJ, Carroll JS, Bailey TL, Koopman P, Jauch R, Cooper MA, Gambin Y, Francois M. Overman J, et al. Among authors: mittal d. Elife. 2017 Jan 31;6:e21221. doi: 10.7554/eLife.21221. Elife. 2017. PMID: 28137359 Free PMC article.

2

Targeting cancer-derived adenosine: new therapeutic approaches.

Young A, Mittal D, Stagg J, Smyth MJ. Young A, et al. Among authors: mittal d. Cancer Discov. 2014 Aug;4(8):879-88. doi: 10.1158/2159-8290.CD-14-0341. Epub 2014 Jul 17. Cancer Discov. 2014. PMID: 25035124 Review.

3

Overcoming Acquired PD-1/PD-L1 Resistance with CD38 Blockade.

Mittal D, Vijayan D, Smyth MJ. Mittal D, et al. Cancer Discov. 2018 Sep;8(9):1066-1068. doi: 10.1158/2159-8290.CD-18-0798. Cancer Discov. 2018. PMID: 30181171

4

New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape.

Mittal D, Gubin MM, Schreiber RD, Smyth MJ. Mittal D, et al. Curr Opin Immunol. 2014 Apr;27:16-25. doi: 10.1016/j.coi.2014.01.004. Epub 2014 Feb 14. Curr Opin Immunol. 2014. PMID: 24531241 Free PMC article. Review.

5

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor.

Mittal D, Young A, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ. Mittal D, et al. Cancer Res. 2014 Jul 15;74(14):3652-8. doi: 10.1158/0008-5472.CAN-14-0957. Epub 2014 Jul 1. Cancer Res. 2014. PMID: 24986517 Free article.

6

Co-blockade of immune checkpoints and adenosine A_2A receptor suppresses metastasis.

Young A, Mittal D, Stannard K, Yong M, Teng MW, Allard B, Stagg J, Smyth MJ. Young A, et al. Among authors: mittal d. Oncoimmunology. 2014 Dec 15;3(10):e958952. doi: 10.4161/21624011.2014.958952. eCollection 2014 Nov. Oncoimmunology. 2014. PMID: 25941583 Free PMC article.

7

Blockade of ErbB2 and PD-L1 using a bispecific antibody to improve targeted anti-ErbB2 therapy.

Mittal D, Vijayan D, Neijssen J, Kreijtz J, Habraken MMJM, Van Eenennaam H, Van Elsas A, Smyth MJ. Mittal D, et al. Oncoimmunology. 2019 Aug 26;8(11):e1648171. doi: 10.1080/2162402X.2019.1648171. eCollection 2019. Oncoimmunology. 2019. PMID: 31646095 Free PMC article.

8

Improved Treatment of Breast Cancer with Anti-HER2 Therapy Requires Interleukin-21 Signaling in CD8+ T Cells.

Mittal D, Caramia F, Michiels S, Joensuu H, Kellokumpu-Lehtinen PL, Sotiriou C, Loi S, Smyth MJ. Mittal D, et al. Cancer Res. 2016 Jan 15;76(2):264-74. doi: 10.1158/0008-5472.CAN-15-1567. Epub 2016 Jan 7. Cancer Res. 2016. PMID: 26744522

9

CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity.

Roman Aguilera A, Lutzky VP, Mittal D, Li XY, Stannard K, Takeda K, Bernhardt G, Teng MWL, Dougall WC, Smyth MJ. Roman Aguilera A, et al. Among authors: mittal d. Oncoimmunology. 2018 Feb 1;7(5):e1424677. doi: 10.1080/2162402X.2018.1424677. eCollection 2018. Oncoimmunology. 2018. PMID: 29721390 Free PMC article.

10

Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy.

Blake SJ, Stannard K, Liu J, Allen S, Yong MC, Mittal D, Aguilera AR, Miles JJ, Lutzky VP, de Andrade LF, Martinet L, Colonna M, Takeda K, Kühnel F, Gurlevik E, Bernhardt G, Teng MW, Smyth MJ. Blake SJ, et al. Among authors: mittal d. Cancer Discov. 2016 Apr;6(4):446-59. doi: 10.1158/2159-8290.CD-15-0944. Epub 2016 Jan 19. Cancer Discov. 2016. PMID: 26787820

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

246 results

Search Page